Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older ...

Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of Medicine alumnus and professor emeritus ...

Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge, gene-editing therapy fashioned ...

The grantmaking organization Open Philanthropy has awarded funding for a University of California San Diego technology ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...

PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...

Learn why research that continues to look for new substrate alternatives is essential to the future of growing.

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...